The Effect of MRSA Nasal Screen Implementation on Duration of Therapy and Cost Associated With Vancomycin Use.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Methodist Health System
- Enrollment
- 21
- Locations
- 1
- Primary Endpoint
- Duration of therapy
Study Overview
Brief Summary
To evaluate the impact of MRSA nasal screen implementation on duration of therapy and cost associated with vancomycin use.
Detailed Description
Routine blood and sputum cultures are often obtained inpatient for critically ill pneumonia patients. These tests, however, tend to have a high yield of false positives, leading to an increase in the use of broad spectrum antibiotics, specifically vancomycin. The Methicillin-resistant Staphylococcus aureus(MRSA) nasal screen is an antimicrobial stewardship tool that can be used to guide the treatment of community-acquired, hospital-acquired and ventilator-associated pneumonia. Due to its strong negative predictive value; a negative result can accurately indicate the absence of an MRSA infection in 96% of cases. Long-term treatment with vancomycin in patients with pneumonia is nephrotoxic and not always warranted. The implementation of an MRSA nasal screen in all patients with pneumonia treated with vancomycin has the potential to reduce vancomycin duration of therapy, decrease the risk of adverse effects and decrease the cost associated with vancomycin use.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age > 18 years
- •Diagnosis of pneumonia
- •Admission inpatient to Methodist Richardson Medical Center
- •Treatment with vancomycin empirically
Exclusion Criteria
- •Age ≤ 18 years
- •Patients with other confirmed gram positive infections
Arms & Interventions
The direct cost of vancomycin
The direct cost of vancomycin for each patient will then be calculated. An average duration of therapy and the average cost of therapy per patient will be calculated.
Intervention: Duration of therapy (Other)
The direct cost of vancomycin
The direct cost of vancomycin for each patient will then be calculated. An average duration of therapy and the average cost of therapy per patient will be calculated.
Intervention: Direct Cost (Other)
The direct cost of vancomycin
The direct cost of vancomycin for each patient will then be calculated. An average duration of therapy and the average cost of therapy per patient will be calculated.
Intervention: Pharmacokinectic Monitoring (Other)
The direct cost of vancomycin
The direct cost of vancomycin for each patient will then be calculated. An average duration of therapy and the average cost of therapy per patient will be calculated.
Intervention: Hospital stay (Other)
Outcomes
Primary Outcomes
Duration of therapy
Time Frame: 1 year
To analyze duration of vancomycin in days.
Secondary Outcomes
No secondary outcomes reported